Kristof Van Emelen

Kristof Van Emelen brings over 25 years of experience in drug discovery, early-stage drug development and executive leadership. Before joining Obulytix, he served as Vice President Drug Discovery at Scenic Biotech, working on first-in-class small molecule modalities as therapeutic solutions for rare diseases. Prior to his tenure with Scenic Biotech, Kristof held senior leadership roles at Ermium Therapeutics, and as Entrepreneur-in-Residence at the VIB. Between 1997 and 2017, Kristof served in various scientific and leadership positions at Johnson & Johnson, across different therapeutic areas. Dr. Van Emelen holds a PhD in Organic Chemistry from KU Leuven.